Imatinib and second generation tyrosine kinase inhibitors has dramatically improved outcomes in patients with chronic myeloid leukemia but allogeneic hematopoietic stem cell transplantation remains an important treatment option in patients who failed imatinib and or second generation second generation tyrosine kinase inhibitors or progressed accelerated and blastic phase. This article provides recommendations regarding the selection of allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia based on the evaluation of published articles and expert recommendations.
INTRODUCTION
While Imatinib (IM) or second generation tyrosine kinase inhibitors (Dasatinib, Nilotinib) supplant the allogeneic hematopoietic stem cell transplantation (allo-SCT) in newly diagnosed chronic myeloid leukemia (CML), some patients are known to be still refractory to imatinib (IM) and tyrosine kinase inhibitors (TKIs). [1] [2] [3] Patients refractory to IM treatment compose 35% of CML patients and half of these patients are also refractory second generation TKIs. [3] [4] [5] [6] The mortality risk of the allogeneic transplant has decreased continuous-ly during the last 20 years. The reasons for the dramatic improvements include better human leukocyte antigen typing, more careful patient selection and improved supportive care. Reduced leukemia burden by imatinib, nilotinib or dasatinib prior to transplantation may also have contributed to current TRM rates of less than 10% in CP-CML patients. 4, 6 In this respect, a literature based summary of indication and timing of allogeneic hematopoietic stem cell transplantation in treatment refractory patients is presented in this paper based on the identification of these patients in the first place or with respect to response obtained during the follow up.
Transplant Related Factors
Certain factors related to allogeneic BMT methodology including donor selection, source of stem cell, preparation regime and measures used to reduce the risk of graft versus host disease influence the success of stem cell transplantation. 3, 4, 7 While bone marrow is recommended source of stem cell for the first chronic phase, use of stem cells obtained from the peripheral circulation is associated with better outcome in advanced phase CML. 4, [7] [8] [9] Notably, there is an ongoing debate on the inclusion of myeloablative and non-myeloablative preparation regimes. In this regard, decrease in toxicity was reported with patient-dependent dose adjustment of busulfan while preparation regimes were recommended to target the increase of graft versus leukemia effect which has been considered to be more effective in the eradication of the disease compared with high dose chemotherapy. Accordingly, fludarabine containing protocols become the preferred preparation regimes. Additionally, preparation regimes based on T lymphocyte depletion were documented to be associated with retarded immune recovery and increased risk of infection and relapse. Treatment with imatinib before allogeneic SCT had a positive impact on the probability of survival and second generation tyrosine kinase inhibitors before allogeneic SCT do not adversely affect allogeneic SCT. 4, 5, 6, 8, 9 
Prognostic Scores and Allogeneic Stem Cell Transplantation
Considering factors related to prognosis; age, spleen size, the ratio of blast in the peripheral blood and thrombocyte count demonstrated by Sokal et al was followed by addition of two other factors as basophil and eosinophil counts by Hasford et al. Besides, a scoring system was identified by Gratwohl et al considering age of the patient, type of the donor, phase of the disease, time from the initial diagnosis and gender of the donor in male patients. Indicating better survival following allogeneic SCT in patients with lower scores such as 0.1, the relation of this scoring system to allogeneic BMT-survival was demonstrated. 1, 4, 10, 11 Detailed information about Sokal and Hasfford risk calculation, accelerated phase and blastic phase definitions [11] [12] , transplantation-EMBT risk calculation, imatinib failure, indications for transplanta- Failure to achieve complete hematologic response by 3rd month Failure to achieve major cytogenetic response by 12 months Failure to achieve a complete cytogenetic response by 18 months 
Donor-recipient gender difference
Female donor, male recipient 1
Other combination 0
Time from diagnosis to transplantation < 12 months 0 > 12 months 1 Table 6 . Indications for transplantation in the first chronic, accelerated and blastic phases of the disease
Indications for transplantation

First chronic phase
While not recommended without imatinib treatment, excluding patients with T315I mutation, if patient refuses to receive imatinib treatment and prefer transplantation despite explanation of all of the related risks, it can be performed.
Under imatinib treatment: if refractoriness develops, patient is evaluated for second generation TKI treatment as well as allogeneic SCT. Allogeneic SCT is recommended in imatinib refractory patients with mutation and low EBMT score (0-2). According to
Hammersmith scoring system, allogeneic SCT is preferred in patients having high sokal risk score, developing neutropenia during imatinib treatment, and more importantly having inadequate cytogenetic response with imatinib besides low EBMT score.
Patients administered with second generation TKI following imatinib treatment or patients with suboptimal response under second generation TKI treatment according to ELN criteria.
Accelerated phase
Allogeneic SCT is indicated but treatment with high dose imatinib (600 mg) or with second generation TKI in refractory patients to enable hematologic, cytogenetic and molecular remission before the transplantation increases the transplantation success.
Blastic phase
Allogeneic SCT is indicated following achievement of chronic or accelerated phase of the disease by high dose imatinib (600 mg), second generation TKI or combination chemotherapy. Table 7 . Indications for tyrosine kinase inhibitor treatment following allogeneic stem cell transplantation, age criteria for transplantation and timing of donor search
Indications for tyrosine kinase inhibitor treatment following transplantation
It is recommended as a prophylactic treatment in patients with allogeneic stem cell transplantation due to positive ALL and blastic phase CML.
Patients with cytogenetic and molecular relapse following transplantation Patients with suboptimal response to second generation TKIs and EBMT score 0-2 tion in the first chronic, accelerated phase and blastic phases of the disease, indications for the treatment with tyrosine kinase inhibitors after allogeneic stem cell transplantation, age criteria for transplantation and timing of donor search are summarized in Tables 1-7 .
The Value of Post Transplant Use of TKI
It is recommended as a prophylactic treatment in patients with allogeneic stem cell transplantation due to positive ALL and blastic phase CML or patients with cytogenetic and molecular relapse following transplantation. Articles related the use of imatinib and second-generation TKIs in the post-SCT setting are limited. The incidence of GVHD in patients treated with Imatinib and second-generation TKIs post transplant is not yet known. Imatinib and second-generation TKIs during the post-SCT can cause pancytopenia, QTC prolongation, cardiotoxicity, liver dysfunction, fluid retention and nausea but the drugs is generally well tolerated. It is also unclear whether post-SCT Imatinib and second-generation TKIs alone is sufficient to induce durable remissions. Between Imatinib and secondgeneration TKIs, Dasatinib crosses the blood-brain barrier and has a role in the treatment of extramedullary relapse. Imatinib and second-generation TKIs do not eradicate the leukemic stem cell and donor lymphocyte infusions can be given for this purpose. More studies are warranted to identify the best time post-SCT to initiate therapy with TKIs, long-term side effects, treatment duration. 6, 7, 13 
CONCLUSION
Early identification of poor risk CML patients for allo-SCT is important. Evaluating the hematologic, molecular and cytogenetic response to Imatinib and second generation tyrosine kinase inhibitors and prognostic factors are useful for deciding allogeneic BMT in patients with CML.
